ELTX · Elicio Therapeutics, Inc.
$3.04
-0.04 (-1.14%)
At close · Aug 21
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$80.82M
Shares
26.28M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2024-03-29 | New | Biotechnology | $6,000,000 | $6,000,000 | 06b |
| 2024-01-05 | New | Biotechnology | $7,047,530 | $7,047,530 | 06b |
| 2020-06-23 | New | Biotechnology | $40,000,000 | $6,695,000 | 06b |
| 2020-01-27 | New | Biotechnology | $12,000,000 | $1,000,000 | 06b |
| 2020-01-13 | New | Biotechnology | $12,000,000 | $6,081,980 | 06b |
Showing 1–5 of 5 filings
Key facts
CIK
1601485
CUSIP
28657F103
13F (30d)
50 filings
50 filers
Visit website
Investor relations